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A b s t r a c t
Background: Arterial hypertension is one of the main causes of cardiovascular disease morbidity and overall mortality. 
Aim: To report the single centre experiences with changes in arterial blood pressure (BP) in patients after intra-arterial ap-
plication of radiofrequency (RF) energy to cause renal sympathetic efferent and somatic afferent nerve and report vascular 
and kidney safety in a six month follow up. 
Methods: Twenty-eight patients, with hypertension despite medical therapy (median age 52.02 years, range 42–72 years) 
consented to therapeutic renal nerve ablation. SIMPLICITY RF catheters and generator provided by Ardian (currently Medtronic 
Inc., USA) were used to perform renal artery angiography and ablation. 
Results: The mean BP at baseline, and after one month, three months and six months were measured [mm Hg]: systolic 
176.6; 162.3 (p = 0.004); 150.6 (p < 0.001); 147.2 (p < 0.001); diastolic 100.2; 90.3 (p < 0.001); 91.79 (p = 0.03); 
88.5 (p < 0.001); pulse pressure 76.57; 75.18 (p = NS); 65.80 (p < 0.001); 62.15 (p < 0.001). Neither procedure-related 
nor therapy-related complications were reported in the six month follow up.
Conclusions: In our cohort of patients, intra-arterial renal nerve denervation was not associated with either vascular or renal 
complications out to six months. Nerve ablation of renal arteries led to significant reduction of mean values of arterial systolic, 
diastolic BP and significant reduction of pulse pressure. The Polish experience is not significantly different compared to that 
reported in the Symplicity I and Symplicity II international cohorts. The long term durability of this therapy and its application 
to earlier stages of hypertension or other disease states will require further investigation. 
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INTRODUCTION
Arterial hypertension is one of the main causes of cardiovascu-
lar disease morbidity and overall mortality, including cerebral, 
cardiac, renal and peripheral vascular diseases. Despite the 
broad availability of numerous classes of hypotensive medi-
cations, half of all hypertensive patients never achieve the 
recommended levels of blood pressure (BP) [1, 2]. Patient 
non-compliance with diet, exercise and medical therapy is 
often cited as a significant contribution to this failure. How-
ever, therapeutic inertia and possible adverse events related to 
lifelong poly pharmacy are also likely. Regardless of the cause 
of therapeutic failure, hypertensive patients remain at excess 
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risk of renal failure, stroke or myocardial infarction (MI), and 
it remains a vital healthcare priority to identify alternative and 
successful treatment options for these patients. 
Selectively disabling the renal sympathetic fibres (RD, 
renal denervation) using a straightforward intra-arterial ap-
proach offers significant potential to improve BP manage-
ment in pharmaceutical-resistant patients, as well as offering 
a therapeutic option for patients who choose not to be, or 
cannot be, compliant with a lifelong poly pharmacy strategy 
for BP control. The concept of sympathetic denervation is 
not new since radical sympathectomy has been applied in 
patients with resistant malignant hypertension. However, 
the new availability of a simple approach and selective renal 
nerve ablation offer the potential advantages of the surgical 
approach without the surgical morbidity and complications 
associated with non-selective sympathetic denervation [3].
A recently introduced method of percutaneous cathe-
ter-based intraluminal selective sympathetic nerve ablation of 
renal arteries using radiofrequency (RF) current is gaining more 
attention. Initial studies using this method have shown [4–6] 
effective reduction of sympathicomimetic activity and renin 
secretion as well as an acceptable safety profile and significant 
reduction in BP levels without major adverse outcomes. 
The aim of this study was to assess changes in arterial 
BP levels in patients after ablation of nerve terminalis in re-
nal arteries (denervation) as well as procedure safety in a six 
month follow up.
METHODS
The primary enrollment criterion was the presence of resistant 
arterial hypertension, defined as mean brachial artery seated 
systolic pressure above 160 mm Hg during out-patient depart-
ment visits, despite historical compliance with at least three anti-
hypertensive drugs (including a diuretic) in optimal doses. Other 
enrollment criteria are listed in Table 1. BP measurement was 
always performed with an automatic device with a printer 
— OMRON 7051T, by the same person after ten minutes of 
rest, three times at five-minute intervals. In order to qualify each 
patient for the invasive procedure and assess the effect of the 
procedure, a mean value of three measurements was taken into 
consideration. Patients with renal failure and renal artery disease 
or with anatomic contraindications to safe ablation (renal artery 
lumen diameter < 4 mm, double or narrow renal arteries, criti-
cal stenosis) were excluded (see Table 1 for exclusion criteria). 
Four weeks before the invasive procedure, the mean values of 
BP in all subjects were stable and pharmacological treatment 
remained unchanged. No changes in pharmacotherapy were 
recommended in the follow up period after the procedure. 
Twenty-eight patients (median age 52.02 years, range 
42–72 years) with diagnosed arterial hypertension resistant 
to pharmacological treatment were identified and consented 
to therapeutic RD and the follow up procedures. Baseline 
characteristics are presented in Table 2. 
Table 1. Inclusion and exclusion criteria
Inclusion criteria
1. Patients over 18 years with systolic blood pressure over 160 mm Hg
2. Patients receiving full doses of three antihypertensive drugs 
(including a diuretic) for at least two weeks before enrollment
3. Estimated glomerular filtration rate over 45 mL/min
4. Written consent
Exclusion criteria
1. Renal arteries anomalies:
a. Haemodynamically significant renal artery stenosis  
(over 50%) by visual assessment
b. Atherosclerotic lesion or stenosis within the artery which 
may potentially, according to the operator, add additional 
hazard to patient safety during artery catheterisation 
c. Haemodynamically or physiologically significant stenosis 
which may be responsible for arterial hypertension
d. Prior renal artery stenting or angioplasty
e. Patients with more than one renal artery at one side
2. Suspicion of secondary hypertension or diagnosed secondary 
hypertension regardless of the underlying cause (including one 
associated with administered drugs)
3. Patients with history of coronary artery disease manifested by 
myocardial infarction, unstable angina or stroke in the previous 
six months
4. Patients with significant valvular disease
5. Type 1 diabetes
6. Patients with implantable cardioverter-defibrillator or pacemaker
7. Patients requiring breathing support
8. Patients suffering from a disease or taking drugs which may 
potentially influence the effectiveness of the therapy  
(e.g. peripheral atherosclerosis, aortic aneurysm, bleeding  
disorders, thrombocytopenia, anaemia, arrhythmia, alcohol 
abuse, drug addiction)
9. Patients who plan pregnancy or are pregnant
Height ranged from 147 to 184 cm (mean value 167.8 cm); 
weight ranged from 60 to 122 kg (mean value 89.5 kg). The 
co-existing comorbidities included: hypercholesterolaemia was 
diagnosed in 20 patients, diabetes mellitus type 2 in seven, and 
peptic ulcer disease in three. Nine patients had prior symptoms 
of coronary artery disease, of whom one had suffered from MI 
and had had percutaneous coronary intervention with stent 
implantation; another had had prior coronary artery bypass 
surgery. One patient had mild aortic valve stenosis, and one 
had asthma and chronic obstructive pulmonary disease. Only 
two patients were diagnosed with chronic renal insufficiency 
according to elevated creatinine and urea in blood serum. No 
patient had symptoms of peripheral artery disease. The NYHA 
scale was 1.8 for this cohort of patients (range 1 to 3). The mean 
value of three measurements of BP before ablation was: systolic 
from 160 to 212 mm Hg (mean value 176.6 mm Hg), diastolic 
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from 84 to 121 mm Hg (mean value 100.28 mm Hg). The 
heart rate ranged from 60 to 98/min (mean value 73.4/min).
The procedure was performed in the usual manner. 
SIMPLICITY catheters and generators were delivered by the 
Ardian company (currently Medtronic Inc., USA). All proce-
dures were performed via femoral artery following adminis-
tration of unfractionated heparin (100 U/kg), a standard for 
renal artery angiography. There were up to six two-minute 
pre-programmed applications of RF energy treatments in each 
renal artery, with a maximum 8 W energy. 
The six ablations were performed in a helical pattern, 
separated by 5 mm. The temperature at the tip of the catheter 
was monitored by the ablation system as well as tissue resist-
ance to guide therapeutic and safe application of energy by 
a provided and programmed generator algorithm. After the 
procedure, patients were followed up in visits at one, three 
and six months. BP measurements were performed (according 
to the methodology described earlier), blood count, electro-
lytes, urea, creatinine and urine were evaluated at each visit, 
as well as physical exam including orthostatic BP measures. 
Patients were monitored for major adverse cardiac events 
such as death, stroke, MI or outcomes associated with the 
procedure itself, such as retroperitoneal bleeding, renal artery 
stenosis, and access site complications. 
This paper is a subanalysis of the patients recruited to 
the SIMPLICITY study published in the Lancet in 2009 [4]. 
The study was approved by the Bioethics Committee at the 
Jagiellonian University in Krakow, Poland. 
Statistical analysis
For statistical analysis, we assessed continuous variables be-
tween groups, including the primary endpoint, with Student’s 
two-sample t test. We compared categorical variables with 
Fisher’s exact test; for within group paired data, a paired 
t test was used. Two-sided alpha level of 0.05 was used for 




There were no access site complications or significant vascular, 
renal or cardiovascular adverse events reported. During the 
procedure, many patients reported epigastric diffuse pain 
predictably starting after each ablation and ending promptly 
with the end of therapy. Pre procedure sedatives and amne-
sics were used in all patients and supplemental intravenous 
opioids were used in most. 
All 28 patients were discharged home 2–5 days after the 
procedure (mean stay was 3.1 days). The hospitalisation length 
was unrelated to the procedure. 
One month after the procedure
Twenty-one patients were seen by protocol one month after 
the procedure. Their weight ranged from 72 to 120 kg (mean 
value 89.22 kg) and was not statistically different from baseline 
before the procedure. In this cohort of patients, the mean 
value of BP was: systolic from 135 to 185 mm Hg (mean 
value 162.3 mm Hg), and diastolic from 77 to 103 mm Hg 
(mean value 90.3 mm Hg); this was a mean reduction of 
14.3 mm Hg in systolic and 10.02 mm Hg in diastolic BP 
compared to baseline values. These changes were statistically 
significant. The mean pulse pressure was 75.18 mm Hg. Of 
the 21 patients, six (28%) had more than a 10 mm Hg fall in 
systolic BP (Table 3, Fig. 1).
The mean values of heart rate ranged from 60 to 80/min 
(mean value 72/min) during the one month check-up visit. 
The mean heart rate was 0.6 bpm lower than the baseline 
heart rate value, although this was not statistically significant. 
No crucial changes in pharmacotherapy or dosages of 
drugs were noted, nor any complications related to the proce-
dure. One patient reported chest pain in the month following 
the procedure, but neither non-invasive tests nor subsequent 
coronary angiography revealed significant coronary artery 
disease or recent MI. The pain was adjudicated as unrelated 
to the procedure. 
Urine sample tests were within standards. Baseline blood 
parameters did not reveal a rise in renal parameters used to 
detect for renal failure. 
Table 2. Baseline characteristics
Patient numbers (men, women) 28 (16 male, 12 female) 
Age (mean) [years] 42–72 (52.02)
Height (mean) [cm] 147–184 (167.8)
Weight (mean) [kg] 60–122 (89.5)
Abdominal obesity (waist  
circumference > 102 cm in men, 
88 > cm in women)
6 (21%)
Hypercholesterolaemia 20 (71%)
Current smoking (number of patients)  2 (7%)
Impaired glucose tolerance 1 (3%)
Diabetes mellitus type II  7 (25%)
Coronary artery disease 9 (32%)
Peptic ulcer 3 (10%)
Aortic stenosis 1 (3%)
Asthma, chronic obstructive pulmo-
nary disease
1 (3%)
Creatinine [µmol/L] 53.0–123.0 (mean 85.6)
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Three months after the procedure
Three months after the procedure, 27 patients who had 
ablation performed were followed up. One patient stopped 
taking all prescribed medications and was excluded from the 
three-month analysis. All other patients remained on baseline 
pharmacotherapy, except for a single patient who had nitren-
dipine eliminated due to low BP. 
The mean value of systolic BP for the remaining 26 pa-
tients ranged from 120 to 230 mm Hg (mean value 150.69 mm 
Hg) and was 26 mm Hg lower than baseline (Table 3, Fig. 1). 
The mean value of diastolic BP for the remaining 26 patients 
ranged from 70 to 120 mm Hg (mean value 91.79 mm Hg) 
and was 8.52 mm Hg lower than baseline. 
The mean pulse pressure decreased to 65.86 mm Hg. 
The mean values of heart rate ranged from 52 to 100/min 
(mean value 74.39/min) during the three-month check-up 
visit. The mean heart rate did not differ from baseline and 
was statistically not significant. 
No complications related to the ablation procedure nor 
adverse events were noted. 
Urine sample tests were within standards. Baseline blood 
parameters did not reveal a rise in renal parameters used to 
detect for renal failure. The weight ranged from 71 to 105 kg 
(mean value 90 kg) and was not statistically different from 
baseline before the procedure. 
Six months after the procedure
Six months after the procedure, 26 patients were seen in 
follow up. All patients remained compliant with baseline 
pharmacotherapy. 
The mean value of systolic BP for the 26 patients ranged 
from 120 to 190 mm Hg (mean value 147.2 mm Hg) and was 
29.4 mm Hg lower than baseline (Table 3, Fig. 1). The mean 
value of diastolic BP for the 26 patients ranged from 70 to 
115 mm Hg (mean value 88.5 mm Hg) and was 11.78 mm Hg 
lower than baseline before the ablation procedure. The pulse 
pressure decreased to 62.15 mm Hg (mean value) from base-
line 76.57 mm Hg (Table 3). Systolic, diastolic BP and pulse 
pressure were statistically significantly lower than at baseline.
The mean values of heart rate ranged from 56 to 104/min 
(mean value 71.96/min) during the six-month follow up. The 
mean heart rate was 1.44 bpm lower than that measured 
before the procedure (statistically not significant).
No complications related to the ablation procedure nor 
adverse events were noted. 
Urine samples tested six months after the procedure were 
within standards. Baseline blood parameters did not reveal 
a rise in renal parameters used to detect for renal failure. The 
weight six months after the procedure ranged from 60 to 
126 kg (mean value 90.3 kg) and was not statistically different 
from the mean value before the procedure. 
DISCUSSION
The results of our study are in line with previously published 
data [4, 5], which have shown statistically significant BP reduc-
tion after renal artery denervation with RF current in patients 
with arterial hypertension resistant to pharmacotherapy. 
The significant reduction in BP was confirmed during 
out-patient visits after standardised measurements in pa-
Table 3. Blood pressure changes, weight and heart rhythm changes
Baseline 1 month 3 months 6 months
N 28 21 26 26
Systolic blood pressure  
(mean, median) [mm Hg]
160–212 (176.6, 175) 135–162.3 (162.3, 170) 120–230 (150.69, 150) 120–190 (147.2, 146,5)
Diastolic blood pressure  
(mean, median) [mm Hg]
84–121 (100.28, 98.5) 77–103 (90.3, 92) 70–120 (91.79, 92) 70–115 (88.5, 90)
Pulse pressure  
(mean) [mm Hg]
56–100 (76.57) 52–93 (75.18) 36–118 (65.80) 35–90 (62.15)
Heart rhythm (mean) [bpm] 60–98 (73.4) 60–80 (72) 52–100 (74.39) 56–104 (71.96)
Weight (mean) [kg] 60–120 (89.5) 72–120 (89.22) 71–105 (90) 60–126 (90.3)
Figure 1. Mean systolic, diastolic blood pressure (BP) and heart 
rate at baseline and 1, 3 and 6 months after the procedure
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tients receiving stable antihypertensive pharmacotherapy. In 
our study, RD led to 29.4 mm Hg decrease in systolic and 
11.78 mm Hg decrease in diastolic BP, which was significant 
compared to baseline value (Fig. 1). This reduction of systolic 
and diastolic BP corresponds to a significant reduction of pulse 
pressure of 14.42 mm Hg (p < 0.001). No adverse outcomes, 
complications such as renal failure, or clinically relevant renal 
artery stenosis occurred during follow up. 
This Polish report is comparable to the international 
randomised clinical trial [6]. RD turned out to be a treat-
ment method with sustainable BP decrease in patients 
with resistant hypertension. After a two-year follow up, 
observation of 153 patients in whom baseline BP was 
176/98 ± 17/15 mm Hg, a mean decrease of 32/14 mm Hg, 
was achieved which was statistically significant. 
Among patients from the Simplicity I and Simplicity II 
trials assessed together, 84% of patients had durable lowering 
of BP (mean decrease in systolic BP was 32 mm Hg, and for 
the diastolic BP 12 mm Hg after six months; p < 0.001) [7].
There is a cardiovascular mortality and cardiovascular mor-
bidity benefit from a successful BP lowering therapy (systolic, 
diastolic and pulse pressure) [8–12]. The effect on all-cause 
mortality is less pronounced, while the reduction of mortality is 
principally related to a reduction of cerebrovascular events. Meta 
analysis supports a 2% reduction of mortality for every 1 mm Hg 
reduction of systolic BP. The obvious BP lowering, especially 
the pulse pressure, certainly reflects future risk benefit for these 
patients, however, it is as yet too early to estimate the overall 
outcome of adverse events such as death, stroke and MI in long 
term observation in this smaller series. Nonetheless, the patients 
enrolled had exhausted alternative therapy, and RD has provided 
a calculable benefit in this cohort. 
None of the current reports identify serious adverse 
events of the procedure, while several note transient brady-
cardia pseudoaneurysms in access site, rapid onset hypotonia, 
urinary tract infections, parestesia and pain, all self limited 
complications. Out of 206 patients who had denervation 
performed in the analysis of published studies, only five had 
complications in the form of pseudoaneurysms and dissection 
of renal artery caused by the ablation catheter [12].
To date, no long term vascular or renal complications 
have been identified [13]. The ablation itself is sterile, and 
preclinical trials show healed non-inflammatory lesions with 
mature fibrosis at the ablation sites, suggesting that there is 
little risk of late vascular complications. There is a theoretical 
potential for efferent sympathetic fibres to regrow, but it is 
generally felt that afferent fibres cannot. The recent report of 
sustained BP reduction out to three years (ACC 2012) confirms 
the durability of the procedure [14]. 
The benefits of RD may not be confined to the reduction 
of BP. Metabolic effect in hypertensive patients and associated 
with improvement of glucose tolerance and sleep apnoea was 
confirmed by Witkowski et al. [15] and in a study of RD in pa-
tients with polycystic ovary syndrome [16]. The improvement 
on glucose tolerance was not associated with current therapy 
with insulin or oral drugs which has also been confirmed in 
other studies [17]. In our study, however, no observation 
focused on glucose tolerance was undertaken. 
The potential of RD for patients who are persistently 
non-compliant, or who have proved intolerant to medications, 
has not been explored and the value of the therapy in patients 
with secondary hypertension, such as aldosteronism, remains 
to be investigated. Also, the value of this therapy in earlier 
non-resistant hypertension remains unexplored.
The role of sympathetic efferent and afferent somatic 
fibres in hypertension has long been proved in animal models, 
where efferent signals increase renin release, cause a right-
ward shift of the pressure natriuresis curve, and reduce renal 
bloodflow. Interfering with the deleterious effects of these 
signals may explain much of the underlying mechanism of 
BP reduction seen in this trial. Moreover, the potential of 
the kidney to modify the central sympathetic state via signals 
from its resident afferent somatic chemo and mechanorecep-
tors is intriguing. The reduction of total body noradrenaline 
and muscle sympathetic nerve activity supports this novel 
hypothesis [4, 6, 18]. 
If true, then the selective reduction of renal signalling 
to the hypothalamus may have value in the treatment of 
other disorders related to sympathetic hyperactivity, such 
as heart failure with preserved or reduced ejection fraction, 
hypertrophic heart disease, and ventricular hypertrophy, 
tachyarrhythmias, post myocardial ventricular dilation, insulin 
resistance, advancing chronic renal disease, and polycystic 
ovary syndrome. 
CONCLUSIONS
Denervation (ablation) of sympathetic fibres in renal arteries 
was a safe procedure in this cohort of patients. Selective renal 
nerve ablation with RF energy via the renal artery using the 
Ardian system (Medtronic) led to significant and sustained 
decreases in mean values of arterial systolic and diastolic 
BP and pulse pressure in a six month follow up in patients 
with resistant hypertension with optimal pharmacotherapy 
compared to baseline measurements. In the absence of suc-
cessful pharmacotherapy in this population, the procedure 
now adds benefit to their care. Certainly long term vascular 
and renal safety data will be required. The application of 
this therapy to patients whose BP has not proved resistant to 
life-long polypharmacy, or additional disease states such as 
heart failure, insulin resistance or type 2 diabetes, post myo-
cardial ventricular dilation, tachycardia arrhythmias such as 
atrial fibrillation, and polycystic ovary syndrome, will require 
further investigation. 
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Denerwacja (ablacja) zakończeń nerwowych  
w tętnicach nerkowych: wczesne wyniki  
interwencyjnego leczenia nadciśnienia tętniczego
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S t r e s z c z e n i e
Wstęp: Nadciśnienie tętnicze jest jednym z najważniejszych czynników ryzyka rozwoju chorób układu sercowo-naczyniowego 
i zgonu. 
Cel: Celem pracy była ocena zmian ciśnienia tętniczego u pacjentów poddanych procedurze ablacji zakończeń nerwowych 
w okolicy tętnic nerkowych (denerwacji) oraz ocena bezpieczeństwa wykonania procedury w czasie 6-miesięcznej kontroli 
pooperacyjnej. 
Metody: Do procedury ablacji zakończeń nerwowych w okolicy tętnic nerkowych zakwalifikowano 28 pacjentów w wieku 
42–72 lat (śr. 52,02 roku) ze zdiagnozowanym nadciśnieniem tętniczym, opornym na leczenie zachowawcze. Do wykona-
nia angiografii tętnic nerkowych i procedury ablacji użyto cewnika SIMPLICITY firmy Ardian (obecnie Medtronic Inc. USA). 
Wyniki: Średnie ciśnienie tętnicze przed procedurą, po 1, 3 i 6 miesiącach po procedurze wynosiły odpowiednio [mm Hg]: 
skurczowe: 176,6; 162,3 (p = 0,004); 150,6 (p < 0,001); 147,2 (p < 0,001); rozkurczowe: 100,2; 90,3 (p < 0,001); 
91,79 (p = 0,03); 88,5 (p < 0,001); ciśnienie tętna: 76,57; 75,18 (p = NS); 65,80 (p < 0,001); 62,15 (p < 0,001). Nie 
odnotowano istotnych powikłań po wykonaniu procedury i w czasie 6-miesięcznej kontroli pooperacyjnej. 
Wnioski: W niniejszej pracy ablacja splotów nerwowych tętnic nerkowych nie wiązała się z wystąpieniem powikłań naczy-
niowych i nerkowych do 6. miesiąca od procedury. Ablacja nerwów okolicy tętnic nerkowych prowadzi do istotnego spadku 
skurczowego i rozkurczowego ciśnienia tętniczego i ciśnienia tętna. Polskie doświadczenie nie różni się znacząco od wyników 
dotyczących pozostałej grupy chorych, uzyskanych w międzynarodowych badaniach Symplicity I and Symplicity II. Długo-
trwała kontrola kliniczna jest konieczna w celu oceny trwałości leczenia i wystąpienia ewentualnych powikłań odległych.
Słowa kluczowe: nadciśnienie tętnicze, nadciśnienie nerkopochodne, nadciśnienie lekooporne, ablacja tętnic nerkowych
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